Investors
Latest results
As a listed entity, we have a responsibility to communicate our strategy and performance to investors in order to promote confidence. Information for investors includes share information, share analysis, shareholder news and annual reports.
We’re confident in our future
Our bold ambitions for patients are reflected in new commitments to growth and a significant step-change in delivery over the next five years.
Pakistan Stock Exchange Symbol
GLAXO
Compliance Certificate
Corporate Briefing Session GSK Pakistan
- Briefing Presentation 2024(PDF - 1.1MB)
- Briefing Letter 2024
- Briefing Presentation 2023
- Briefing Letter 2023(PDF - 772.1KB)
- Briefing Presentation 2022 (PDF - 1.5MB)
- Briefing Letter 2022 (PDF - 585.8KB)
- Briefing Presentation 2021 (PDF - 2.2MB)
- Briefing Letter 2021 (PDF - 602.3KB)
- Briefing Presentation 2020 (PDF - 2.2MB)
- Briefing Letter 2020 (PDF - 129.1KB)
For complaints or queries please contact:
Ms. Hina Mir
Company Secretary
Email: PK.Shareinfo@gsk.com
Phone No: +9221 111 475 725
DISCLAIMER: “In case your complaint has not been properly redressed by us, you may lodge your complaint with Securities and Exchange Commission of Pakistan (the “SECP”). However, please note that SECP will entertain only those complaints which were at first directly requested to be redressed by the Company and the company has failed to redress the same. Further, the complaints that are not relevant to SECP’s regulatory domain/competence shall not be entertained.”
Financial highlights
Key operation and financial data
